Literature DB >> 23958451

Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma.

Donna L Savigni1, Ryan L O'Hare Doig1, Charis R Szymanski1, Carole A Bartlett1, Ivan Lozić2, Nicole M Smith2, Melinda Fitzgerald3.   

Abstract

Following neurotrauma, cells beyond the initial trauma site undergo secondary degeneration, with excess Ca2+ a likely trigger for loss of neurons, compact myelin and function. Treatment using inhibitors of specific Ca2+ channels has shown promise in preclinical studies, but clinical trials have been disappointing and combinatorial approaches are needed. We assessed efficacy of multiple combinations of three Ca2+ channel inhibitors at reducing secondary degeneration following partial optic nerve transection in rat. We used lomerizine to inhibit voltage gated Ca2+ channels; oxidised adenosine-triphosphate (oxATP) to inhibit purinergic P2X7 receptors and/or 2-[7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-1,2,3,4-tetrahydro quinoxalin-1-yl]acetic acid (INQ) to inhibit Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Only the three Ca2+ channel inhibitors delivered in combination significantly preserved visual function, as assessed using the optokinetic nystagmus visual reflex, at 3 months after injury. Preservation of retinal ganglion cells was partial and is unlikely to have accounted for differential effects on function. A range of the Ca2+ channel inhibitor combinations prevented swelling of optic nerve vulnerable to secondary degeneration. Each of the treatments involving lomerizine significantly increased the proportion of axons with normal compact myelin. Nevertheless, limiting decompaction of myelin was not sufficient for preservation of function in our model. Multiple combinations of Ca2+ channel inhibitors reduced formation of atypical node/paranode complexes; outcomes were not associated with preservation of visual function. However, prevention of lengthening of the paranodal gap that was only achieved by treatment with the three Ca2+ channel inhibitors in combination was an important additional effect that likely contributed to the associated preservation of the optokinetic reflex using this combinatorial treatment strategy.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-[7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-1,2,3,4-tetrahydro quinoxalin-1-yl]acetic acid; AMPA; ATP; Ca(2+) channel inhibitors; INQ; Lom; Myelin; Myelin compaction; N-methyl-d-aspartic acid; NMDA; Neurotrauma; Node/paranode complex; OCT; ON; OPCs; Oxidative stress; PBS; PFA; PT; RGC; SEM; Secondary degeneration; TEM; VGCCs; Visual system; adenosine triphosphate; i.p.; intraperitoneally; lomerizine; oligodendrocyte precursor cells; optic nerve; optical cutting temperature; oxATP; oxidised adenosine-triphosphate; paraformaldehyde; partial transection; phosphate buffered saline; retinal ganglion cell; standard error of the mean; transmission electron microscopy; voltage-gated calcium channels; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

Mesh:

Substances:

Year:  2013        PMID: 23958451     DOI: 10.1016/j.neuropharm.2013.07.034

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

Review 1.  Psychophysical testing in rodent models of glaucomatous optic neuropathy.

Authors:  Stephanie L Grillo; Peter Koulen
Journal:  Exp Eye Res       Date:  2015-07-02       Impact factor: 3.467

2.  Clinical characteristics of optic neuritis in Hong Kong population: 10-year review.

Authors:  Bonnie Nga Kwan Choy; Alex Lap Ki Ng; Jimmy Shiu Ming Lai
Journal:  Int Ophthalmol       Date:  2017-03-13       Impact factor: 2.031

3.  Attenuation of Axonal Degeneration by Calcium Channel Inhibitors Improves Retinal Ganglion Cell Survival and Regeneration After Optic Nerve Crush.

Authors:  Vinicius T Ribas; Jan C Koch; Uwe Michel; Mathias Bähr; Paul Lingor
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

4.  Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.

Authors:  Lillian M Toomey; Carole A Bartlett; Maimuna Majimbi; Gopana Gopalasingam; Jennifer Rodger; Melinda Fitzgerald
Journal:  Exp Brain Res       Date:  2018-10-26       Impact factor: 1.972

Review 5.  Influence of Trace Elements on Neurodegenerative Diseases of The Eye-The Glaucoma Model.

Authors:  Agnieszka Kamińska; Giovanni Luca Romano; Robert Rejdak; Sandrine Zweifel; Michal Fiedorowicz; Magdalena Rejdak; Anahita Bajka; Rosario Amato; Claudio Bucolo; Teresio Avitabile; Filippo Drago; Mario Damiano Toro
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

6.  Direct optic nerve sheath (DONS) application of Schwann cells prolongs retinal ganglion cell survival in vivo.

Authors:  L Guo; B Davis; S Nizari; E M Normando; H Shi; J Galvao; L Turner; J Shi; M Clements; S Parrinello; M F Cordeiro
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

Review 7.  Mechanisms of secondary degeneration after partial optic nerve transection.

Authors:  Hong-Ying Li; Yi-Wen Ruan; Chao-Ran Ren; Qi Cui; Kwok-Fai So
Journal:  Neural Regen Res       Date:  2014-03-15       Impact factor: 5.135

8.  Role of P2X7 receptors in neuronal death in the retina.

Authors:  Tetsuya Sugiyama
Journal:  Neural Regen Res       Date:  2014-03-15       Impact factor: 5.135

9.  Strategies to limit dysmyelination during secondary degeneration following neurotrauma.

Authors:  Melinda Fitzgerald
Journal:  Neural Regen Res       Date:  2014-06-01       Impact factor: 5.135

10.  An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles.

Authors:  Nicole M Smith; Ivana Gachulincova; Diwei Ho; Charlotte Bailey; Carole A Bartlett; Marck Norret; John Murphy; Alysia Buckley; Paul J Rigby; Michael J House; Timothy St Pierre; Melinda Fitzgerald; K Swaminathan Iyer; Sarah A Dunlop
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.